An Open-label, Exploratory, Phase II, Proof-of Concept, Clinical Study to Assess the Safety and Tolerability of EI-1071 in Patients with Alzheimer's Disease (AD)
Latest Information Update: 26 Dec 2024
Price :
$35 *
At a glance
- Drugs Enrupatinib (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Elixiron Immunotherapeutics
- 26 Dec 2024 New trial record